Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 5, 2004, Pages 596-600

  Yamamoto, Takashi ^a   Wada, Atsuyuki ^a   Tsutamoto, Takayoshi ^a   Ohnishi, Masato ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

cGMP; Heart failure; Natriuretic peptides; Phosphodiesterase type 5; Pulmonary hypertension

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; CYCLIC GMP; HS 142 1; METHYL 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINE CARBOHYDRATE SULFATE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOG; ENZYME INHIBITION; HEART FAILURE; HEMODYNAMICS; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIAC PACING, ARTIFICIAL; CYCLIC GMP; DISEASE MODELS, ANIMAL; DOGS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; HEART FAILURE, CONGESTIVE; HEART RATE; HEART VENTRICLES; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; ISOQUINOLINES; JAPAN; LUNG; MYOCARDIAL CONTRACTION; NATRIURETIC PEPTIDES; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; POLYSACCHARIDES; PYRIDINES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; TIME FACTORS; VASCULAR RESISTANCE;

EID: 7444248877     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200411000-00013     Document Type: Article

References (30)

1. Abramson SV, Burke JF, Kelly JJ Jr, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992;116:888-895.
2. Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure. Science. 1986;231:1145-1147.
3. Waldman SA, Raport RM, Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem. 1984;259:14332-14334.
4. Wada A, Tsutamoto T, Matsuda Y, et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation. 1994;89:2232-2240.
5. Tsutamoto T, Kanamori T, Wada A, et al. Uncoupling of atrial natriuretic peptide excretion and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol. 1992;20:541-546.
6. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
7. Takagi M, Mochida H, Noto T, et al. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. Eur J Pharmacol. 2001;411:161-168.
8. Dundore RL, Clas DM, Wheeler LT, et al. Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats. Eur J Pharmacol. 1993; 249:293-297.
9. Cohen AH, Hanson K, Morris K, et al. Inhibition of cyclic 3′-5′-guanosine monophosphete-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest. 1996;97:172-179.
10. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104:424-428.
11. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360:895-900.
12. Wada A, Tsutamoto T, Ohnishi M, et al. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure. Circulation. 1999;99:570-577.
13. Kotera J, Fujishige K, Michibata H, et al. Characterization and effects of methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5- trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibition of cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Pharmacol. 2000;60:1333-1341.
14. Morishita Y, Sano T, Ando K, et al. Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor. Biochem Biophys Res Commun. 1991;176:949-957.
15. Jernigan NL, Resta TC. Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation. Am J Physiol. 2002;282:L1366-L1375.
16. Hanson KA, Ziegler JW, Rybalkin SD, et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol. 1998;275:L931-L941.
17. Ignarro LJ, Harbison RG, Wood KS, et al. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intra-pulmonary artery and vein: Stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther. 1986;237:893-899.
18. Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation. 1994; 90:2780-2785.
19. Loh E, Lankford EB, Polidori DJ, et al. Cardiovascular effects of inhaled nitric oxide in a canine model of cardiomyopathy. Ann Thorac Surg. 1999;67:1380-1385.
20. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002; 105:2398-2403.
21. Barst RJ, Rubin LJ, McGoon MD, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-301.
22. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134: 44-54.
23. Montalescot G, Drobinski G, Meurin P, et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol. 1998;82:749-755.
24. Inoue H, Yano K, Noto T, et al. T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters. Eur J Pharmacol. 2002;443:179-184.
25. Senzaki H, Smith CJ, Juang GJ, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 2001;15:1718-1726.
26. Phillips BG, Kato M, Pesek CA, et al. Sympathetic activation by sildenafil. Circulation. 2000;102:3068-3073.
27. Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: A double-blind, placebo-controlled, randomized study followed by prospective treatment for erectile dysfunction. Circulation. 2002;106: 1097-1103.
28. Katz SD, Biasucci L, Sabba C, et al. Impaired endotherium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol. 1992;19:918-925.
29. Kats SD, Balidemaj K, Homma S, et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-851.
30. Lisy O, Lainchbury JG, Leskinen H, et al. Therapeutic action of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001; 37:1089-1094.